These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4026546)

  • 1. [Protein binding of drugs in continuous ultrafiltration. 6. Protein binding of acenocoumarol].
    Rehse K; Ehlert K
    Arch Pharm (Weinheim); 1985 Jun; 318(6):574-4. PubMed ID: 4026546
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of the plasma protein binding of the coumarin anticoagulants phenprocoumon and its metabolites, warfarin and acenocoumarol, by ultrafiltration and high-performance liquid chromatography.
    de Vries JX; Völker U
    J Chromatogr; 1990 Aug; 529(2):479-85. PubMed ID: 2229265
    [No Abstract]   [Full Text] [Related]  

  • 3. Inverse stereoselectivity in the binding of acenocoumarol to human serum albumin and to alpha 1-acid glycoprotein.
    Fitos I; Visy J; Magyar A; Kajtár J; Simonyi M
    Biochem Pharmacol; 1989 Jul; 38(14):2259-62. PubMed ID: 2751692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective distribution of acenocoumarol enantiomers in human plasma: chiral chromatographic analysis of the ultrafiltrates.
    Fitos I; Visy J; Simonyi M; Hermansson J
    Chirality; 1993; 5(5):346-9. PubMed ID: 8398591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation and pharmacokinetics of acenocoumarol (Sintrom) in man.
    Dieterle W; Faigle JW; Montigel C; Sulc M; Theobald W
    Eur J Clin Pharmacol; 1977; 11(5):367-75. PubMed ID: 328289
    [No Abstract]   [Full Text] [Related]  

  • 6. Determination of protein binding of gyrase inhibitors by means of continuous ultrafiltration.
    Zlotos G; Oehlmann M; Nickel P; Holzgrabe U
    J Pharm Biomed Anal; 1998 Dec; 18(4-5):847-58. PubMed ID: 9919987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of plasma protein binding for sympathomimetic drugs by means of ultrafiltration.
    Volpp M; Holzgrabe U
    Eur J Pharm Sci; 2019 Jan; 127():175-184. PubMed ID: 30391401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Protein binding of drugs determined by continuous ultrafiltration. I. Protein binding of phenprocoumon].
    Rehse K; Rothe M; Maurer R; Kinawi A
    Arch Pharm (Weinheim); 1981 Oct; 314(10):867-74. PubMed ID: 7305640
    [No Abstract]   [Full Text] [Related]  

  • 9. Ultrafiltration in serum protein binding determinations.
    Whitlam JB; Brown KF
    J Pharm Sci; 1981 Feb; 70(2):146-50. PubMed ID: 7205216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vacuum ultrafiltration sampling for determination of plasma protein binding of drugs.
    Lam H; Davies M; Lunte CE
    J Pharm Biomed Anal; 1996 Sep; 14(12):1753-7. PubMed ID: 8887723
    [No Abstract]   [Full Text] [Related]  

  • 11. Sensitive stereospecific determination of acenocoumarol and phenprocoumon in plasma by high-performance liquid chromatography.
    Rentsch KM; Gutteck-Amsler U; Bührer R; Fattinger KE; Vonderschmitt DJ
    J Chromatogr B Biomed Sci Appl; 2000 May; 742(1):131-42. PubMed ID: 10892592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and qualitative analysis of the anticoagulant acenocoumarol in human plasma.
    van Kempen GM; Koot-Gronsveld EA; de Wolfe FA
    J Chromatogr; 1978 Mar; 145(2):332-5. PubMed ID: 649730
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.
    van den Bongard HJ; Sparidans RW; Critchley DJ; Beijnen JH; Schellens JH
    Invest New Drugs; 2004 Apr; 22(2):151-8. PubMed ID: 14739663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma protein binding of warfarin: methodological considerations.
    Mungall D; Wong YY; Talbert RL; Crawford MH; Marshall J; Hawkins DW; Ludden TM
    J Pharm Sci; 1984 Jul; 73(7):1000-1. PubMed ID: 6470938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLC determination of plasma acenocoumarol levels.
    Midha KK; Cooper JK
    J Pharm Sci; 1977 Jun; 66(6):799-802. PubMed ID: 874778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of benazepril, a converting enzyme inhibitor, on plasma levels and activity of acenocoumarol and warfarin.
    Van Hecken A; De Lepeleire I; Verbesselt R; Arnout J; Angehrn J; Youngberg C; De Schepper PJ
    Int J Clin Pharmacol Res; 1988; 8(5):315-9. PubMed ID: 3229872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of acenocoumarol in plasma by reversed-phase high-performance liquid chromatography.
    Wong LT; Solomonraj G
    J Chromatogr; 1979 May; 163(1):103-8. PubMed ID: 528620
    [No Abstract]   [Full Text] [Related]  

  • 18. Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma.
    Peláez EC; Estevez MC; Portela A; Salvador JP; Marco MP; Lechuga LM
    Biosens Bioelectron; 2018 Nov; 119():149-155. PubMed ID: 30125875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting ultrafiltration-assessed values for drug binding.
    Tasker RA; Nakatsu K
    Clin Chem; 1982 May; 28(5):1244-6. PubMed ID: 7074924
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacology studies with acenocoumarol.
    Hirtz J; Le Roux Y; Jaouen A; Richard J; Blatrix C; Thébault JJ; Schoeller JP
    Int J Clin Pharmacol Biopharm; 1979 Aug; 17(8):361-5. PubMed ID: 489204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.